---
figid: PMC6746687__430_2018_570_Fig3_HTML
figlink: /pmc/articles/PMC6746687/figure/Fig3/
number: F3
caption: A schematic diagram of EB virus involved in the G1/S transition. Epstein–Barr
  virus infection is an early event in the development of malignancies. The latent
  proteins and miRNAs encoded by EBV in host cells alone or in combination drive the
  cell cycle through a variety of pathways. LMP-1 regulates telomerase activity through
  the p16INK4A/Rb/E2F1 signaling pathway to promote cell immortalization. LMP-2A couples
  with c-Myc to promote G1/S transition and hyperproliferation of B lymphocytes through
  promoting the expression of cyclin D and the degradation of p27kip1 at the early
  stage of oncogenesis. The cell cycle regulatory protein E2F1, the E2F-binding protein
  ARID3A, and the B-cell-specific transcription factor Oct-2 bind EBNA-1, which are
  necessary for transcriptional activation. EBNA-1 also enhances expression of LMP-1,
  and then promotes cell proliferation. The interaction between EBNA-2, EBNA-3C, and
  c-Myc further activates cyclin D2 and CDK4, then promoting the cell from G1 phase
  into S phase. EBNA-3A and EBNA-3C down-regulate the expression of p15INK4b, p16INK4a,
  and p14ARF, thereby inhibiting apoptosis. EBAN-3C can directly bind to p53, to a
  certain extent, inhibit its transcriptional activity. EBERs can up-regulate Bcl-2
  and down-regulate p21cip1 and p27kip1, thereby releasing the inhibition of CDK4
  and CDK2 and promoting the cell cycle from G1 phase to S phase. EBV-miR-BHRF1 inhibits
  apoptosis in B lymphocytes and epithelial cells. EBV-miR-BARTs can target caspase
  3, thereby inhibiting apoptosis and increasing the number of cells entering the
  S phase
pmcid: PMC6746687
papertitle: Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis.
reftext: Huali Yin, et al. Med Microbiol Immunol. 2019;208(5):573-583.
pmc_ranked_result_index: '24353'
pathway_score: 0.9543041
filename: 430_2018_570_Fig3_HTML.jpg
figtitle: Schematic diagram of EB virus involved in the G1/S transition
year: '2019'
organisms:
- Homo sapiens
ndex: ac3f1f54-deeb-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6746687__430_2018_570_Fig3_HTML.html
  '@type': Dataset
  description: A schematic diagram of EB virus involved in the G1/S transition. Epstein–Barr
    virus infection is an early event in the development of malignancies. The latent
    proteins and miRNAs encoded by EBV in host cells alone or in combination drive
    the cell cycle through a variety of pathways. LMP-1 regulates telomerase activity
    through the p16INK4A/Rb/E2F1 signaling pathway to promote cell immortalization.
    LMP-2A couples with c-Myc to promote G1/S transition and hyperproliferation of
    B lymphocytes through promoting the expression of cyclin D and the degradation
    of p27kip1 at the early stage of oncogenesis. The cell cycle regulatory protein
    E2F1, the E2F-binding protein ARID3A, and the B-cell-specific transcription factor
    Oct-2 bind EBNA-1, which are necessary for transcriptional activation. EBNA-1
    also enhances expression of LMP-1, and then promotes cell proliferation. The interaction
    between EBNA-2, EBNA-3C, and c-Myc further activates cyclin D2 and CDK4, then
    promoting the cell from G1 phase into S phase. EBNA-3A and EBNA-3C down-regulate
    the expression of p15INK4b, p16INK4a, and p14ARF, thereby inhibiting apoptosis.
    EBAN-3C can directly bind to p53, to a certain extent, inhibit its transcriptional
    activity. EBERs can up-regulate Bcl-2 and down-regulate p21cip1 and p27kip1, thereby
    releasing the inhibition of CDK4 and CDK2 and promoting the cell cycle from G1
    phase to S phase. EBV-miR-BHRF1 inhibits apoptosis in B lymphocytes and epithelial
    cells. EBV-miR-BARTs can target caspase 3, thereby inhibiting apoptosis and increasing
    the number of cells entering the S phase
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CDK2
  - CDKL1
  - CDK3
  - CDK6
  - MYC
  - CCNA1
  - CDK4
  - CCND1
  - CCND2
  - CCND3
  - CCNA2
  - ARID3A
  - ATM
  - BCL2
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - CDK5
  - CDK7
  - CDK8
  - CCNE1
  - CCNE2
  - E2F1
  - E2F7
  - CDKL3
  - CDK16
  - CDK17
  - CDK18
  - CDK12
  - CDK14
  - CDK15
  - CDKL5
  - CDK11A
  - CDK10
  - CDK13
  - CDKL2
  - CDK1
  - CDK11B
  - CDKN2A
  - CDKN1B
  - TP53
  - PCNA
  - CDK9
  - CDK19
  - E2F6
  - E2F8
  - CDK20
  - CDKL4
  - EBNA
  - EBNA-3C
  - Cancer
  - Melanoma
genes:
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK2
  entrez: '1017'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDKL1
  entrez: '8814'
- word: CDK2
  symbol: CDK2
  source: hgnc_symbol
  hgnc_symbol: CDK2
  entrez: '1017'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK3
  entrez: '1018'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: C-myc
  symbol: c-Myc
  source: hgnc_alias_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: CyclinA
  symbol: Cyclin_A
  source: bioentities_symbol
  hgnc_symbol: CCNA1
  entrez: '8900'
- word: CDK4/6
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND2
  entrez: '894'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND3
  entrez: '896'
- word: CyclinA
  symbol: Cyclin_A
  source: bioentities_symbol
  hgnc_symbol: CCNA2
  entrez: '890'
- word: ARID3A
  symbol: ARID3A
  source: hgnc_symbol
  hgnc_symbol: ARID3A
  entrez: '1820'
- word: ATM
  symbol: ATM
  source: hgnc_symbol
  hgnc_symbol: ATM
  entrez: '472'
- word: Bcl-2
  symbol: Bcl-2
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK5
  entrez: '1020'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK7
  entrez: '1022'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK8
  entrez: '1024'
- word: CyclinE
  symbol: Cyclin_E
  source: bioentities_symbol
  hgnc_symbol: CCNE1
  entrez: '898'
- word: CyclinE
  symbol: Cyclin_E
  source: bioentities_symbol
  hgnc_symbol: CCNE2
  entrez: '9134'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDKL3
  entrez: '51265'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK16
  entrez: '5127'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK17
  entrez: '5128'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK18
  entrez: '5129'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK12
  entrez: '51755'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK14
  entrez: '5218'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK15
  entrez: '65061'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDKL5
  entrez: '6792'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK11A
  entrez: '728642'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK10
  entrez: '8558'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK13
  entrez: '8621'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDKL2
  entrez: '8999'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK1
  entrez: '983'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK11B
  entrez: '984'
- word: P14ARF
  symbol: p14ARF
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: p16
  symbol: p16
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: p27Kip1
  symbol: P27KIP1
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN1B
  entrez: '1027'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: PCNA
  symbol: PCNA
  source: hgnc_symbol
  hgnc_symbol: PCNA
  entrez: '5111'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK9
  entrez: '1025'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK19
  entrez: '23097'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: E2F1-3
  symbol: E2F3
  source: hgnc_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK20
  entrez: '23552'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDKL4
  entrez: '344387'
- word: E2F1-2
  symbol: E2F2
  source: hgnc_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F1-2
  symbol: E2F1
  source: hgnc_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
chemicals:
- word: EBNA
  source: MESH
  identifier: C417029
- word: EBNA-3C
  source: MESH
  identifier: C417029
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Melanoma
  source: ''
  identifier: ''
figid_alias: PMC6746687__F3
redirect_from: /figures/PMC6746687__F3
figtype: Figure
---
